← Leaderboards
Dao Pan
Cincinnati Childrens Hosp Med Ctr
$6,892,530
Attributed
$7,099,758
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $642.9K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,099,758 · 6
By mechanism
R01$5,581,276 · 3
P01$557,484 · 1
R56$556,500 · 1
R21$404,498 · 1
Top collaborators
- Gregory A. Grabowski1 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Stephanie L Merhar$10,001,417
Others in their field
Top investigators on “Gene Transfer”
- David Heimbrook · Leidos Biomedical Research, Inc.$217,080,250
- Jeffrey P Krischer · University Of South Florida$141,198,102
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$72,179,157
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$51,608,818
- Keri Hammel · The Emmes Company, Llc$47,641,358
Research focus
Gene TransferCellsNovel StrategiesBlood - Brain Barrier AnatomyMediatingEnzymesBrainLysosomal Storage DiseasesIn VivoHematopoietic Stem Cell TransplantationL-IduronidaseMetabolicNervous System DisorderTraffickingProductionNeurologicPreclinical EvaluationProteinsTransgene ExpressionMouse ModelGene TherapyLentivirus VectorErythroidMucopolysaccharidosis I
Grant awards (27)
Advancing CNS drug delivery via epigenetic modulation$511,676
R01 · FY2025 · NS · contact PI
Advancing CNS drug delivery via epigenetic modulation$131,265
R01 · FY2025 · NS · contact PI
Advancing CNS drug delivery via epigenetic modulation$551,474
R01 · FY2024 · NS · contact PI
Advancing CNS drug delivery via epigenetic modulation$90,721
R01 · FY2024 · NS · contact PI
Advancing CNS drug delivery via epigenetic modulation$583,654
R01 · FY2023 · NS · contact PI
Manipulation of microRNA for CNS delivery: implication to treatment of neurological LSD$556,500
R56 · FY2020 · NS · contact PI
Gaucher disease:Treatment of neurodegenerative disease$414,457
R01 · FY2017 · NS · contact PI
Gaucher disease:Treatment of neurodegenerative disease$414,457
R01 · FY2016 · NS · contact PI
Gaucher disease:Treatment of neurodegenerative disease$414,457
R01 · FY2015 · NS · contact PI
Gaucher disease:Treatment of neurodegenerative disease$410,311
R01 · FY2014 · NS · contact PI
Gaucher disease:Treatment of neurodegenerative disease$414,457
R01 · FY2013 · NS · contact PI
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery$321,563
R01 · FY2012 · NS · contact PI
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery$321,563
R01 · FY2011 · NS · contact PI
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery$324,845
R01 · FY2010 · NS · contact PI
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery$328,125
R01 · FY2009 · NS · contact PI
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery$20,126
R01 · FY2009 · NS · contact PI
Genetic Therapy for CNS Manifestations in MPS I via BBB-targeted Protein Delivery$328,125
R01 · FY2008 · NS · contact PI
Core--Real-time quantitative PCR$73,032
P01 · FY2008 · HD · contact PI
Core--Real-time quantitative PCR$72,346
P01 · FY2007 · HD · contact PI
In Vivo BM Stem Cell Gene Transfer for MPS type I$218,248
R21 · FY2006 · AI · contact PI
Core--Real-time quantitative PCR$68,543
P01 · FY2006 · HD · contact PI
In Vivo BM Stem Cell Gene Transfer for MPS type I$186,250
R21 · FY2005 · AI
Core--Real-time quantitative PCR$66,547
P01 · FY2005 · HD
Core--Real-time quantitative PCR$64,608
P01 · FY2004 · HD
Core--Real-time quantitative PCR facility$106,204
P01 · FY2001 · HD
Core--Real-time quantitative PCR facility$0
P01 · FY2001 · HD
Core--Real-time quantitative PCR facility$106,204
P01 · FY2000 · HD